Combining the inhibitor, SP-2509, with neuroblastoma-specific CAR T cells improved their efficacy, especially against neuroblastoma cells with low levels of tumor antigen, where insufficient upregulation of FAS by T cell-produced proinflammatory cytokines was observed. This evidence concerns the gene LINC01194 and neuroblastoma.